B. Riley Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price lifted by equities researchers at B. Riley from $61.00 to $101.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. B. Riley’s price target suggests a potential upside of 50.63% from the company’s current price.

Several other brokerages have also issued reports on ARWR. Chardan Capital raised their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Morgan Stanley boosted their target price on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 7th. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price target (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. The Goldman Sachs Group lifted their price objective on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, January 7th. Finally, Royal Bank Of Canada boosted their price objective on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $81.67.

Arrowhead Pharmaceuticals Stock Down 3.6%

ARWR stock opened at $67.05 on Thursday. The stock has a market cap of $9.11 billion, a P/E ratio of -838.02 and a beta of 1.21. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock’s fifty day simple moving average is $62.41 and its two-hundred day simple moving average is $39.95. Arrowhead Pharmaceuticals has a 1-year low of $9.57 and a 1-year high of $76.76.

Insider Activity

In other news, Director Michael S. Perry sold 16,250 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $61.03, for a total transaction of $991,737.50. Following the completion of the transaction, the director directly owned 115,240 shares in the company, valued at $7,033,097.20. The trade was a 12.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider James C. Hamilton sold 40,164 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the completion of the transaction, the insider directly owned 171,958 shares in the company, valued at approximately $10,852,269.38. The trade was a 18.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 510,836 shares of company stock worth $33,603,060 in the last three months. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. iSAM Funds UK Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $29,000. Salomon & Ludwin LLC purchased a new stake in Arrowhead Pharmaceuticals in the third quarter valued at approximately $34,000. Federated Hermes Inc. bought a new stake in Arrowhead Pharmaceuticals during the third quarter valued at approximately $52,000. Smartleaf Asset Management LLC grew its stake in Arrowhead Pharmaceuticals by 2,186.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,618 shares in the last quarter. Finally, Virtus Advisers LLC purchased a new position in Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $34,000. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals News Roundup

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised several near‑term and FY2026/FY2027 EPS estimates, reiterated a “Buy” rating and a $100 price target — the firm says improving forecasts and program progress support upside. HC Wainwright Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals
• Positive Sentiment: B. Riley bumped its price target to $101 (from $61) and kept a “Buy” stance, implying significant upside from recent levels and signaling continued analyst conviction after Arrowhead’s program updates. B. Riley Raises ARWR Price Target to $101
• Positive Sentiment: Piper Sandler highlighted Arrowhead’s pipeline ahead of Phase III hypertriglyceridemia data and has increased its target (reported lift to $110), underscoring the potential for a clinical readout to re‑rate the stock if data are positive. Piper Sandler Highlights Arrowhead Pipeline
• Neutral Sentiment: Broader coverage pieces (InsiderMonkey/TheFly) recap the analyst upgrades and pipeline milestones — useful for context but largely reiterative of the broker notes above. InsiderMonkey: Piper Sandler Highlights Arrowhead
• Negative Sentiment: Despite the upgrades, shares are down today amid lower‑than‑average volume — likely profit‑taking following the recent run and continued investor caution given persistent GAAP losses and upcoming binary clinical readouts (which carry upside but also clinical risk).

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.